Microchip Exceeds Guidance as Demand Recovery Gains Traction

What happened

Microchip Technology reported March-quarter net sales of $1.311B, up 10.6% sequentially and 35.1% YoY, beating its prior guidance. Management noted improving demand across end markets and normalized distributor inventory, pointing to continued momentum into the June quarter. While these results confirm the stabilization signaled by improving book-to-bill and falling channel inventory, the company's balance sheet remains strained with net debt/EBITDA of 4.7x and interest coverage of only 0.38x. The Tempe Fab 2 closure savings, expected to boost margins, will not impact the income statement until the June 2026 quarter due to FIFO accounting. Therefore, the operational recovery is encouraging but does not yet resolve the financial leverage risk.

Implication

Investors should wait for evidence of sustained demand (book-to-bill consistently >1.05) and meaningful deleveraging (net debt/EBITDA below 3.5x, interest coverage above 2x) before upgrading from WAIT.

Thesis delta

The news confirms the stabilization narrative from the DeepValue report but does not alter the WAIT stance due to persistent balance sheet concerns. The key shift is that demand recovery appears more concrete, but the financial risk remains elevated, reinforcing the need for patience.